The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

The company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues ...

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com. Following these transactions, Bavarian Nordic holds a total of 1,044,510 treasury ...

Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales despite a rise of demand for its mpox vaccines.

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox ...

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA ...

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, ...

Financial guidance for 2025 in line with the Company's 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial ...